...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Testing of a bioactive, moldable bone graft substitute in an infected, critically sized segmental defect model
【24h】

Testing of a bioactive, moldable bone graft substitute in an infected, critically sized segmental defect model

机译：在感染的批判性分段缺陷模型中测试生物活性，可模塑骨移植物的替代品

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Large infected bone defects, often resulting from high energy traumas, are difficult to treat due to their variability in complexity and location. Standard treatment for infected bone defects begins with a protocol that includes a series of debridements in conjunction with an extended course of systemic antibiotics. Only after the infection has been eliminated will repair of the defect commence, typically with implantation of autologous bone. To address some of the shortcomings of the standard treatment methods, such as serial procedures, limited grafting material, and the need for a second surgical site for autologous bone, a sequential, dual drug‐releasing, moldable, calcium sulfate‐based bone graft substitute was developed previously. In the present studies, the effectiveness of the material for treating both the infection with vancomycin and bone defect with simvastatin was evaluated in vivo using a critically sized, infected segmental defect model in rat femurs. Although the infection was not fully eliminated, the local release of vancomycin increased survivorship of infected animals by 464% compared to nontreated controls. Infected animals receiving antimicrobial treatment showed comparable amounts of new bone formation within the defect site when compared to noninfected controls. Incorporating agents capable of disrupting established biofilms into bone graft substitutes may enhance effectiveness in treating a biofilm infection within a bone defect. ? 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1878–1886, 2018.
机译：摘要由于它们在复杂性和位置的可变性而难以治疗大量感染的骨缺陷，通常是难以治疗的。对感染的骨缺陷的标准治疗开始于一种协议，其包括一系列内容与全身抗生素的扩展过程结合。只有在发现感染后，才会修复缺陷的开始，通常具有植入自体骨。解决标准治疗方法的一些缺点，如连续手术，有限的接枝材料，以及对自体骨的第二个外科手术部位的需求，顺序，双药释放，可模塑，硫酸钙基骨移植物替代品以前开发了。在目前的研究中，使用大鼠股骨统治性的受感染的细分缺陷模型，在体内评估治疗与辛霉素和骨缺损的对血霉素和骨缺损的材料的有效性。虽然感染未完全消除，但与非处理对照相比，万古霉素的当地释放增加了464％的感染动物的生存。接受抗微生物处理的受感染的动物在与无活化对照相比，缺陷部位内显示出相当的新骨形成。将能够破坏已建立的生物膜的试剂在骨移植物中可以提高在骨缺损内治疗生物膜感染的有效性。还2017年Wiley期刊，Inc。J生物密制Res B部分：苹果生物摩特，106B：1878-1886,2018。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号